JO3735B1 - مركبات ألكين بها استبدال رباعي واستخداماتها - Google Patents
مركبات ألكين بها استبدال رباعي واستخداماتهاInfo
- Publication number
- JO3735B1 JO3735B1 JOP/2016/0102A JOP20160102A JO3735B1 JO 3735 B1 JO3735 B1 JO 3735B1 JO P20160102 A JOP20160102 A JO P20160102A JO 3735 B1 JO3735 B1 JO 3735B1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds
- tetragonal
- alkenes
- substitution
- breast cancer
- Prior art date
Links
- 150000001336 alkenes Chemical class 0.000 title 1
- RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical group [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 title 1
- 238000006467 substitution reaction Methods 0.000 title 1
- 206010006187 Breast cancer Diseases 0.000 abstract 3
- 208000026310 Breast neoplasm Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 102100038595 Estrogen receptor Human genes 0.000 abstract 1
- 101710196141 Estrogen receptor Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/02—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/02—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
- C07D317/06—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
يتعلق الاختراع الحالي بالكشف عن مركبات، أو أملاح مقبولة صيدلانياً منها، وطرق استخدام المركبات لمعالجة سرطان الثدي بواسطة إعطاء الخاضع الذي بحاجة إلى العلاج كمية فعالة صيدلانياً من المركبات أو الأملاح المقبولة صيدلانياً منها. يمكن أن يكون سرطان الثدي هو سرطان ثدي إيجابي لـ ER و/أو يمكن أن يعبر الخاضع الذي بحاجة إلى المعالجة عن بروتين ER-? به طفرة.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168529P | 2015-05-29 | 2015-05-29 | |
| US201562168581P | 2015-05-29 | 2015-05-29 | |
| US201562269745P | 2015-12-18 | 2015-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3735B1 true JO3735B1 (ar) | 2021-01-31 |
Family
ID=57398096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2016/0102A JO3735B1 (ar) | 2015-05-29 | 2016-05-29 | مركبات ألكين بها استبدال رباعي واستخداماتها |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US9796683B2 (ar) |
| EP (2) | EP3302471B1 (ar) |
| JP (1) | JP6325760B1 (ar) |
| KR (1) | KR102664618B1 (ar) |
| CN (2) | CN113024466A (ar) |
| AU (1) | AU2016271126B2 (ar) |
| BR (1) | BR112017025546B1 (ar) |
| CA (1) | CA2987321C (ar) |
| CL (1) | CL2017002996A1 (ar) |
| CO (1) | CO2017013432A2 (ar) |
| CY (1) | CY1125068T1 (ar) |
| DK (1) | DK3302471T3 (ar) |
| ES (1) | ES2895511T3 (ar) |
| HR (1) | HRP20211542T1 (ar) |
| HU (1) | HUE056199T2 (ar) |
| IL (1) | IL255765B2 (ar) |
| JO (1) | JO3735B1 (ar) |
| LT (1) | LT3302471T (ar) |
| MA (1) | MA43364B1 (ar) |
| MD (1) | MD3302471T2 (ar) |
| MX (1) | MX379297B (ar) |
| MY (1) | MY186977A (ar) |
| PE (1) | PE20181083A1 (ar) |
| PH (1) | PH12017502142B1 (ar) |
| PL (1) | PL3302471T3 (ar) |
| PT (1) | PT3302471T (ar) |
| RS (1) | RS62481B1 (ar) |
| RU (1) | RU2733741C2 (ar) |
| SI (1) | SI3302471T1 (ar) |
| SM (1) | SMT202100599T1 (ar) |
| TW (1) | TWI704137B (ar) |
| UA (1) | UA120882C2 (ar) |
| WO (2) | WO2016196337A1 (ar) |
| ZA (1) | ZA201707912B (ar) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3302471B1 (en) | 2015-05-29 | 2021-08-25 | Eisai R&D Management Co., Ltd. | Tetrasubstituted alkene compounds and their use |
| WO2018098305A1 (en) | 2016-11-24 | 2018-05-31 | Eisai R&D Management Co., Ltd. | Tetrasubstituted alkene compounds and their use for the treatment of breast cancer |
| MA46896A (fr) * | 2016-11-24 | 2019-10-02 | Eisai R&D Man Co Ltd | Composés d'alcène tétrasubstitués et leur utilisation |
| CN109790141B (zh) * | 2016-11-28 | 2021-06-11 | 卫材 R&D 管理有限公司 | 吲唑衍生物的盐及其晶体 |
| BR112019019261A2 (pt) * | 2017-03-16 | 2020-06-16 | Eisai R & D Management Co., Ltd. | Terapias de combinação para o tratamento de câncer de mama |
| CN112566666A (zh) | 2018-05-14 | 2021-03-26 | 努瓦申生物公司 | 靶向抗癌核激素受体的化合物 |
| WO2019225552A1 (en) * | 2018-05-22 | 2019-11-28 | Eisai R&D Management Co., Ltd. | Salts of indazole derivative and crystals thereof |
| CA3122621A1 (en) * | 2018-12-17 | 2020-06-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Estrogen receptor antagonist |
| AU2020274113A1 (en) * | 2019-05-14 | 2021-11-11 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP3976033A1 (en) | 2019-05-24 | 2022-04-06 | Eisai R&D Management Co., Ltd. | A method for treating cancer with an oral dosage form of an estrogen receptor-alpha inhibitor |
| MX2021015486A (es) * | 2019-06-19 | 2022-01-24 | Jiangsu Hengrui Medicine Co | Derivado de indazol, metodo de preparacion y aplicacion farmaceutica del mismo. |
| CN110452177A (zh) * | 2019-09-02 | 2019-11-15 | 南通大学 | 一种5-溴-4-氟-1h-吲唑的合成方法 |
| WO2021097046A1 (en) | 2019-11-13 | 2021-05-20 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP4174059A4 (en) | 2020-06-28 | 2024-07-03 | Medshine Discovery Inc. | INDAZOLE FUSED CYCLIC COMPOUND |
| US20230404987A1 (en) | 2020-11-06 | 2023-12-21 | Eisai R&D Management Co., Ltd. | Method of treating breast cancer |
| CN116615418B (zh) * | 2020-12-18 | 2025-11-11 | 江苏恒瑞医药股份有限公司 | 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法 |
| CN114644615B (zh) * | 2020-12-18 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 一种吲唑类衍生物的结晶形式及其制备方法 |
| CN114644616B (zh) * | 2020-12-18 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法 |
| JP2024510792A (ja) | 2021-03-23 | 2024-03-11 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
| JP2024516024A (ja) | 2021-05-03 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
| CN117440950A (zh) * | 2021-06-27 | 2024-01-23 | 北京盛诺基医药科技股份有限公司 | 一种ERα受体共价结合拮抗剂 |
| CN115960082B (zh) * | 2021-10-13 | 2024-06-07 | 长春金赛药业有限责任公司 | 一种四取代的烯烃化合物、其制备方法及其在医药上的应用 |
| JP2023176261A (ja) * | 2022-05-31 | 2023-12-13 | 東レ・ファインケミカル株式会社 | エチニル基を有する縮合多環芳香族化合物の製造方法 |
| CN117550980B (zh) * | 2023-12-04 | 2025-12-19 | 宁夏瑞泰科技股份有限公司 | 一种制备n-乙基-1,6-己二胺的方法和由其制得的产品 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3907290A1 (de) | 1989-03-07 | 1990-09-13 | Gerhard Prof Dr Eisenbrand | Steroidhormonrezeptoraffine antitumorwirkstoffe |
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| TW397821B (en) | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| WO2009120999A2 (en) | 2008-03-28 | 2009-10-01 | Olema Pharmaceuticals, Inc. | Use of an endoxifen prodrug for treatment of breast cancer |
| US8063249B1 (en) * | 2008-04-25 | 2011-11-22 | Olema Pharmaceuticals, Inc. | Substituted triphenyl butenes |
| CA2775266C (en) | 2009-10-13 | 2013-12-31 | Duquesne University Of The Holy Spirit, A Nonprofit Corporation Organized Under The Laws Of The Commonwealth Of Pennsylvania | Anti-cancer tamoxifen-melatonin hybrid ligand |
| WO2011129837A1 (en) | 2010-04-16 | 2011-10-20 | Olema Pharmaceuticals, Inc. | Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| WO2013056178A2 (en) | 2011-10-14 | 2013-04-18 | Foundation Medicine, Inc. | Novel estrogen receptor mutations and uses thereof |
| JP6154887B2 (ja) | 2012-03-20 | 2017-06-28 | セラゴン ファーマシューティカルズ，インク． | エストロゲン受容体モジュレーターおよびその使用 |
| US9365510B2 (en) | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| MX2015016171A (es) | 2013-06-19 | 2016-08-08 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| SG11201607334YA (en) | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Therapeutic combinations with estrogen receptor modulators |
| WO2016055982A1 (en) | 2014-10-10 | 2016-04-14 | Acerta Pharma B.V. | Quinoline and quinazoline compounds |
| EP3233828B1 (en) | 2014-12-18 | 2020-03-04 | F. Hoffmann-La Roche AG | Estrogen receptor modulators and uses thereof |
| EP3302471B1 (en) | 2015-05-29 | 2021-08-25 | Eisai R&D Management Co., Ltd. | Tetrasubstituted alkene compounds and their use |
-
2016
- 2016-05-27 EP EP16804153.1A patent/EP3302471B1/en active Active
- 2016-05-27 BR BR112017025546-4A patent/BR112017025546B1/pt active IP Right Grant
- 2016-05-27 PH PH1/2017/502142A patent/PH12017502142B1/en unknown
- 2016-05-27 SI SI201631340T patent/SI3302471T1/sl unknown
- 2016-05-27 ES ES16804153T patent/ES2895511T3/es active Active
- 2016-05-27 WO PCT/US2016/034764 patent/WO2016196337A1/en not_active Ceased
- 2016-05-27 CN CN202110301494.7A patent/CN113024466A/zh active Pending
- 2016-05-27 MX MX2017015226A patent/MX379297B/es unknown
- 2016-05-27 HR HRP20211542TT patent/HRP20211542T1/hr unknown
- 2016-05-27 WO PCT/US2016/034782 patent/WO2016196346A1/en not_active Ceased
- 2016-05-27 IL IL255765A patent/IL255765B2/en unknown
- 2016-05-27 JP JP2017560920A patent/JP6325760B1/ja active Active
- 2016-05-27 AU AU2016271126A patent/AU2016271126B2/en active Active
- 2016-05-27 CA CA2987321A patent/CA2987321C/en active Active
- 2016-05-27 UA UAA201712962A patent/UA120882C2/uk unknown
- 2016-05-27 PE PE2017002481A patent/PE20181083A1/es unknown
- 2016-05-27 PT PT168041531T patent/PT3302471T/pt unknown
- 2016-05-27 SM SM20210599T patent/SMT202100599T1/it unknown
- 2016-05-27 MD MDE20180368T patent/MD3302471T2/ro unknown
- 2016-05-27 RU RU2017146408A patent/RU2733741C2/ru active
- 2016-05-27 TW TW105116750A patent/TWI704137B/zh active
- 2016-05-27 KR KR1020177037820A patent/KR102664618B1/ko active Active
- 2016-05-27 HU HUE16804153A patent/HUE056199T2/hu unknown
- 2016-05-27 MY MYPI2017001740A patent/MY186977A/en unknown
- 2016-05-27 RS RS20211306A patent/RS62481B1/sr unknown
- 2016-05-27 CN CN201680043755.7A patent/CN107847498B/zh active Active
- 2016-05-27 PL PL16804153T patent/PL3302471T3/pl unknown
- 2016-05-27 MA MA43364A patent/MA43364B1/fr unknown
- 2016-05-27 US US15/167,373 patent/US9796683B2/en active Active
- 2016-05-27 EP EP21191181.3A patent/EP3981766A1/en not_active Withdrawn
- 2016-05-27 DK DK16804153.1T patent/DK3302471T3/da active
- 2016-05-27 LT LTEPPCT/US2016/034782T patent/LT3302471T/lt unknown
- 2016-05-29 JO JOP/2016/0102A patent/JO3735B1/ar active
-
2017
- 2017-09-22 US US15/713,107 patent/US10851065B2/en active Active
- 2017-11-21 ZA ZA2017/07912A patent/ZA201707912B/en unknown
- 2017-11-27 CL CL2017002996A patent/CL2017002996A1/es unknown
- 2017-12-27 CO CONC2017/0013432A patent/CO2017013432A2/es unknown
-
2021
- 2021-11-08 CY CY20211100961T patent/CY1125068T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3735B1 (ar) | مركبات ألكين بها استبدال رباعي واستخداماتها | |
| EA201691845A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| EA201791516A1 (ru) | Способы комбинированного лечения злокачественных опухолей | |
| EA201491330A1 (ru) | Терапевтически активные соединения и способы их использования | |
| MX383691B (es) | Método de tratamiento de cáncer asociado con una mutación de ras. | |
| MX385283B (es) | Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control. | |
| EA202090098A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| EA201692100A8 (ru) | Новые антитела против rnf43 и способы их применения | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| AU2015267099A8 (en) | Use of eribulin in the treatment of cancer | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| CL2017000050A1 (es) | Terapia de combinación para el cáncer | |
| IN2014MU00303A (ar) | ||
| BR112018011177A2 (pt) | conjugados de citarabina para terapia de câncer | |
| TW201613578A (en) | Pharmaceutical combinations | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| PH12016502243A1 (en) | Pharmaceutical compositions for treating infectious diseases | |
| HK1250626A1 (zh) | 借助塞里班土单抗的组合治疗 | |
| CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| UA116499C2 (uk) | (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині |